Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278198 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02278198 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 5 participants.
The verdict
NCT02278198, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.
Interventions
- DRUG rhTSH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-11-30 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278198
The ClinicalTrials.gov registry entry for NCT02278198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhTSH is the first listed.
NCT02278198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278198 about?
NCT02278198 is a clinical study titled "Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123". The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.
What is the current status of trial NCT02278198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-11-30. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT02278198?
The interventions under investigation include: rhTSH (DRUG).
Who is sponsoring clinical trial NCT02278198?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.